Login Register Cart 0
Generic placeholder image

Current Cancer Drug Targets

Editor-in-Chief

ISSN (Print): 1568-0096
ISSN (Online): 1873-5576

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Transarterial Chemoembolization Followed by Hepatic Arterial Infusion Chemotherapy Combined a Tyrosine Kinase Inhibitor for Treatment of Large Hepatocellular Carcinoma

Author(s): Bin Chen, Haitao Dai, Jianyong Yang, Guiyuan Zhang, Chunyong Wen, Xianhong Xiang, Run Lin* and Yonghui Huang*

Volume 23, Issue 7, 2023

Published on: 15 March, 2023

Page: [564 - 571] Pages: 8

DOI: 10.2174/1568009623666230215142941

Price: $65

Abstract

Objective: Evaluate the efficacy and safety of transarterial chemoembolization (TACE) sequential with hepatic arterial infusion chemotherapy (HAIC) and a tyrosine kinase inhibitor (TKI) for unresectable large hepatocellular carcinoma (HCC).

Methods: Patients with HCC size > 70 mm were included. They received 1-3 cycles of TACE and sequential HAIC every 3-6 weeks for 2-6 cycles, with each cycle given over a period of 48 hours (oxaliplatin plus fluorouracil/leucovorin). Patients also received sorafenib or lenvatinib beginning at the first TACE cycle and continuing until disease progression. Objective response rate (ORR) at 3 months was the primary endpoint. Progression-free survival (PFS) and safety were the secondary endpoints.

Results: From January 2020 to December 2020, 41 patients were included, who were divided into the drug-eluting bead TACE (DEB-TACE) group (n=13) and conventional TACE (cTACE) group (n=28). The overall ORR was 56.1% (23/41) using mRECIST criteria and 34.1% (14/41) using RECIST1.1 criteria. The median PFS of the cohort was 8 months. The ORR of the DEB-TACE group was 76.9% (10/13) vs. 46.4% (13/28) for the cTACE group (p = 0.06). The median PFS of the DEBTACE group was 12 months, and 6 months in the cTACE group (p = 0.09). Conversion hepatectomy was performed in 2 patients in the DEB-TACE group (15.4%), and in 3 patients in the cTACE group (10.7%). ALT/AST elevated, hypertension, nausea, and vomiting were the common treatment related adverse events. There was no treatment related death.

Conclusion: TACE sequential with HAIC combined a TKI is a well-tolerated and promising tripletherapy for large, unresectable HCC.

« Previous Next »
Graphical Abstract

[1]
Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin., 2018, 68(6), 394-424.
[http://dx.doi.org/10.3322/caac.21492] [PMID: 30207593]
[2]
Wang, Q.; Xia, D.; Bai, W.; Wang, E.; Sun, J.; Huang, M.; Mu, W.; Yin, G.; Li, H.; Zhao, H.; Li, J.; Zhang, C.; Zhu, X.; Wu, J.; Li, J.; Gong, W.; Li, Z.; Lin, Z.; Pan, X.; Shi, H.; Shao, G.; Liu, J.; Yang, S.; Zheng, Y.; Xu, J.; Song, J.; Wang, W.; Wang, Z.; Zhang, Y.; Ding, R.; Zhang, H.; Yu, H.; Zheng, L.; Gu, W.; You, N.; Wang, G.; Zhang, S.; Feng, L.; Liu, L.; Zhang, P.; Li, X.; Chen, J.; Xu, T.; Zhou, W.; Zeng, H.; Zhang, Y.; Huang, W.; Jiang, W.; Zhang, W.; Shao, W.; Li, L.; Niu, J.; Yuan, J.; Li, X.; Lv, Y.; Li, K.; Yin, Z.; Xia, J.; Fan, D.; Han, G. Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: A multicentre observational study. J. Hepatol., 2019, 70(5), 893-903.
[http://dx.doi.org/10.1016/j.jhep.2019.01.013] [PMID: 30660709]
[3]
Lyu, N.; Kong, Y.; Mu, L.; Lin, Y.; Li, J.; Liu, Y.; Zhang, Z.; Zheng, L.; Deng, H.; Li, S.; Xie, Q.; Guo, R.; Shi, M.; Xu, L.; Cai, X.; Wu, P.; Zhao, M. Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma. J. Hepatol., 2018, 69(1), 60-69.
[http://dx.doi.org/10.1016/j.jhep.2018.02.008] [PMID: 29471013]
[4]
Lyu, N.; Lin, Y.; Kong, Y.; Zhang, Z.; Liu, L.; Zheng, L.; Mu, L.; Wang, J.; Li, X.; Pan, T.; Xie, Q.; Liu, Y.; Lin, A.; Wu, P.; Zhao, M. FOXAI: A phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma. Gut, 2018, 67(2), 395.1-396.
[http://dx.doi.org/10.1136/gutjnl-2017-314138] [PMID: 28592441]
[5]
Kudo, M.; Finn, R.S.; Qin, S.; Han, K.H.; Ikeda, K.; Piscaglia, F.; Baron, A.; Park, J.W.; Han, G.; Jassem, J.; Blanc, J.F.; Vogel, A.; Komov, D.; Evans, T.R.J.; Lopez, C.; Dutcus, C.; Guo, M.; Saito, K.; Kraljevic, S.; Tamai, T.; Ren, M.; Cheng, A.L. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet, 2018, 391(10126), 1163-1173.
[http://dx.doi.org/10.1016/S0140-6736(18)30207-1] [PMID: 29433850]
[6]
Llovet, J.M.; Ricci, S.; Mazzaferro, V.; Hilgard, P.; Gane, E.; Blanc, J.F.; de Oliveira, A.C.; Santoro, A.; Raoul, J.L.; Forner, A.; Schwartz, M.; Porta, C.; Zeuzem, S.; Bolondi, L.; Greten, T.F.; Galle, P.R.; Seitz, J.F.; Borbath, I.; Häussinger, D.; Giannaris, T.; Shan, M.; Moscovici, M.; Voliotis, D.; Bruix, J. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med., 2008, 359(4), 378-390.
[http://dx.doi.org/10.1056/NEJMoa0708857] [PMID: 18650514]
[7]
Hiraoka, A.; Kumada, T.; Michitaka, K.; Kudo, M. Newly proposed ALBI grade and ALBI-T score as tools for assessment of hepatic function and prognosis in hepatocellular carcinoma patients. Liver Cancer, 2019, 8(5), 312-325.
[http://dx.doi.org/10.1159/000494844] [PMID: 31768342]
[8]
Llovet, J.M.; Real, M.I.; Montaña, X.; Planas, R.; Coll, S.; Aponte, J.; Ayuso, C.; Sala, M.; Muchart, J.; Solà, R.; Rodés, J.; Bruix, J. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial. Lancet, 2002, 359(9319), 1734-1739.
[http://dx.doi.org/10.1016/S0140-6736(02)08649-X] [PMID: 12049862]
[9]
Lo, C.M.; Ngan, H.; Tso, W.K.; Liu, C.L.; Lam, C.M.; Poon, R.T.P.; Fan, S.T.; Wong, J. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology, 2002, 35(5), 1164-1171.
[http://dx.doi.org/10.1053/jhep.2002.33156] [PMID: 11981766]
[10]
Llovet, J.; Bruix, J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology, 2003, 37(2), 429-442.
[http://dx.doi.org/10.1053/jhep.2003.50047] [PMID: 12540794]
[11]
Llovet, J.M.; De Baere, T.; Kulik, L.; Haber, P.K.; Greten, T.F.; Meyer, T.; Lencioni, R. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol., 2021, 18(5), 293-313.
[http://dx.doi.org/10.1038/s41575-020-00395-0] [PMID: 33510460]
[12]
Ueshima, K.; Ogasawara, S.; Ikeda, M.; Yasui, Y.; Terashima, T.; Yamashita, T.; Obi, S.; Sato, S.; Aikata, H.; Ohmura, T.; Kuroda, H.; Ohki, T.; Nagashima, K.; Ooka, Y.; Takita, M.; Kurosaki, M.; Chayama, K.; Kaneko, S.; Izumi, N.; Kato, N.; Kudo, M.; Omata, M. Hepatic arterial infusion chemotherapy versus sorafenib in patients with advanced hepatocellular carcinoma. Liver Cancer, 2020, 9(5), 583-595.
[http://dx.doi.org/10.1159/000508724] [PMID: 33083282]
[13]
Kondo, M.; Morimoto, M.; Kobayashi, S.; Ohkawa, S.; Hidaka, H.; Nakazawa, T.; Aikata, H.; Hatanaka, T.; Takizawa, D.; Matsunaga, K.; Okuse, C.; Suzuki, M.; Taguri, M.; Ishibashi, T.; Numata, K.; Maeda, S.; Tanaka, K. Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial. BMC Cancer, 2019, 19(1), 954.
[http://dx.doi.org/10.1186/s12885-019-6198-8] [PMID: 31615466]
[14]
He, M.K.; Zou, R.H.; Li, Q.J.; Zhou, Z.G.; Shen, J.X.; Zhang, Y.F.; Yu, Z.S.; Xu, L.; Shi, M. Phase II study of sorafenib combined with concurrent hepatic arterial infusion of oxaliplatin, 5-fluorouracil and leucovorin for unresectable hepatocellular carcinoma with major portal vein thrombosis. Cardiovasc. Intervent. Radiol., 2018, 41(5), 734-743.
[http://dx.doi.org/10.1007/s00270-017-1874-z] [PMID: 29327075]
[15]
Qin, S.; Bai, Y.; Lim, H.Y.; Thongprasert, S.; Chao, Y.; Fan, J.; Yang, T.S.; Bhudhisawasdi, V.; Kang, W.K.; Zhou, Y.; Lee, J.H.; Sun, Y. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J. Clin. Oncol., 2013, 31(28), 3501-3508.
[http://dx.doi.org/10.1200/JCO.2012.44.5643] [PMID: 23980077]
[16]
He, M.; Li, Q.; Zou, R.; Shen, J.; Fang, W.; Tan, G.; Zhou, Y.; Wu, X.; Xu, L.; Wei, W.; Le, Y.; Zhou, Z.; Zhao, M.; Guo, Y.; Guo, R.; Chen, M.; Shi, M. Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion. JAMA Oncol., 2019, 5(7), 953-960.
[http://dx.doi.org/10.1001/jamaoncol.2019.0250] [PMID: 31070690]
[17]
Goyal, L.; Zheng, H.; Abrams, T.A.; Miksad, R.; Bullock, A.J.; Allen, J.N.; Yurgelun, M.B.; Clark, J.W.; Kambadakone, A.; Muzikansky, A.; Knowles, M.; Galway, A.; Afflitto, A.J.; Dinicola, C.F.; Regan, E.; Hato, T.; Mamessier, E.; Shigeta, K.; Jain, R.K.; Duda, D.G.; Zhu, A.X. A phase ii and biomarker study of sorafenib combined with modified folfox in patients with advanced hepatocellular carcinoma. Clin. Cancer Res., 2019, 25(1), 80-89.
[http://dx.doi.org/10.1158/1078-0432.CCR-18-0847] [PMID: 30190369]
[18]
Zhang, T.; Merle, P.; Wang, H.; Zhao, H.; Kudo, M. Combination therapy for advanced hepatocellular carcinoma: Do we see the light at the end of the tunnel? Hepatobiliary Surg. Nutr., 2021, 10(2), 180-192.
[http://dx.doi.org/10.21037/hbsn-2021-7] [PMID: 33898559]
[19]
Sato, N.; Beppu, T.; Kinoshita, K.; Yuki, H.; Suyama, K.; Chiyonaga, S.; Motohara, T.; Komohara, Y.; Hara, A.; Akahoshi, S. Conversion hepatectomy for huge hepatocellular carcinoma with arterioportal shunt after chemoembolization and lenvatinib therapy. Anticancer Res., 2019, 39(10), 5695-5701.
[http://dx.doi.org/10.21873/anticanres.13768] [PMID: 31570469]
[20]
Li, B. Conversion to resectability using transarterial chemoembolization combined with hepatic arterial infusion chemotherapy for initially unresectable hepatocellular carcinoma. Ann. Surg., 2021, 2, 1-7.
[21]
Huang, J.; Huang, W.; Zhan, M.; Guo, Y.; Liang, L.; Cai, M.; Lin, L.; He, M.; Lian, H.; Lu, L.; Zhu, K. Drug-eluting bead transarterial chemoembolization combined with folfox-based hepatic arterial infusion chemotherapy for large or huge hepatocellular carcinoma. J. Hepatocell. Carcinoma, 2021, 8, 1445-1458.
[http://dx.doi.org/10.2147/JHC.S339379] [PMID: 34858889]
[22]
Stevens, C.L.; Awad, A.; Abbas, S.M.; Watters, D.A.K. Systematic review and meta-analysis of hepatic resection versus transarterial chemoembolization for solitary large hepatocellular carcinoma. HPB (Oxford), 2017, 19(8), 653-658.
[http://dx.doi.org/10.1016/j.hpb.2017.03.009] [PMID: 28427829]
[23]
Cai, L.; Li, H.; Guo, J.; Zhao, W.; Duan, Y.; Hou, X.; Cheng, L.; Du, H.; Shao, X.; Diao, Z.; Li, C. Drug-eluting bead transarterial chemoembolization is an effective downstaging option for subsequent radical treatments in patients with hepatocellular carcinoma: A cohort study. Clin. Res. Hepatol. Gastroenterol., 2021, 45(4)101535
[http://dx.doi.org/10.1016/j.clinre.2020.09.002] [PMID: 33121882]
[24]
Lammer, J.; Malagari, K.; Vogl, T.; Pilleul, F.; Denys, A.; Watkinson, A.; Pitton, M.; Sergent, G.; Pfammatter, T.; Terraz, S.; Benhamou, Y.; Avajon, Y.; Gruenberger, T.; Pomoni, M.; Langenberger, H.; Schuchmann, M.; Dumortier, J.; Mueller, C.; Chevallier, P.; Lencioni, R. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc. Intervent. Radiol., 2010, 33(1), 41-52.
[http://dx.doi.org/10.1007/s00270-009-9711-7] [PMID: 19908093]
[25]
Golfieri, R.; Giampalma, E.; Renzulli, M.; Cioni, R.; Bargellini, I.; Bartolozzi, C.; Breatta, A.D.; Gandini, G.; Nani, R.; Gasparini, D.; Cucchetti, A.; Bolondi, L.; Trevisani, F. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br. J. Cancer, 2014, 111(2), 255-264.
[http://dx.doi.org/10.1038/bjc.2014.199] [PMID: 24937669]
[26]
Facciorusso, A.; Di Maso, M.; Muscatiello, N. Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma: A meta-analysis. Dig. Liver Dis., 2016, 48(6), 571-577.
[http://dx.doi.org/10.1016/j.dld.2016.02.005] [PMID: 26965785]
[27]
Liu, B.J.; Gao, S.; Zhu, X.; Guo, J.H.; Zhang, X.; Chen, H.; Wang, X.D.; Yang, R.J. Sorafenib combined with embolization plus hepatic arterial infusion chemotherapy for inoperable hepatocellular carcinoma. World J. Gastrointest. Oncol., 2020, 12(6), 663-676.
[http://dx.doi.org/10.4251/wjgo.v12.i6.663] [PMID: 32699581]
[28]
Iezzi, R.; Pompili, M.; La Torre, M.F.; Campanale, M.C.; Montagna, M.; Saviano, A.; Cesario, V.; Siciliano, M.; Annicchiarico, E.; Agnes, S.; Giuliante, F.; Grieco, A.; Rapaccini, G.L.; De Gaetano, A.M.; Gasbarrini, A.; Bonomo, L. Radiofrequency ablation plus drug-eluting beads transcatheter arterial chemoembolization for the treatment of single large hepatocellular carcinoma. Dig. Liver Dis., 2015, 47(3), 242-248.
[http://dx.doi.org/10.1016/j.dld.2014.12.007] [PMID: 25577299]
[29]
Goh, M.J.; Oh, J.H.; Park, Y.; Kim, J.; Kang, W.; Sinn, D.H.; Gwak, G.Y.; Paik, Y.H.; Choi, M.S.; Lee, J.H.; Koh, K.C.; Paik, S.W. Efficacy and safety of lenvatinib therapy for unresectable hepatocellular carcinoma in a real-world practice in Korea. Liver Cancer, 2021, 10(1), 52-62.
[http://dx.doi.org/10.1159/000512239] [PMID: 33708639]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy